C
퓨쳐켐
220100KOSDAQ40.0 / 100
Reference Date: 2026-10-23
Financial Score15.5 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
FutureChem develops radiopharmaceuticals by researching peptides similar to proteins specifically expressed in certain diseases, offering diagnostic and therapeutic drugs. Key products include FC303 for prostate cancer diagnosis and FC705 for treatment, leveraging theranostics technology for personalized medicine. The company utilizes the sCUBE® automated synthesis system to achieve GMP-level manufacturing standards.
Number of Employees
94people
Average Salary
53.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
3.79Industry Average 1.200.0Point
3.2x industry avg (risky)
ROE
-20.50Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
9.30Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲15.9% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲2.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -15.5% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (2%, downtrend)
Current 6,710Won52-week high 34,20052-week low 6,020
1-month return0.0Point
1m -16.33% (strong drop)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0